vs

Side-by-side financial comparison of IRIDEX CORP (IRIX) and Ispire Technology Inc. (ISPR). Click either name above to swap in a different company.

Ispire Technology Inc. is the larger business by last-quarter revenue ($20.3M vs $14.7M, roughly 1.4× IRIDEX CORP). On growth, Ispire Technology Inc. posted the faster year-over-year revenue change (-51.5% vs -69.7%). Over the past eight quarters, IRIDEX CORP's revenue compounded faster (11.9% CAGR vs -17.8%).

IRIDEX Corporation is a global medical technology company that designs, manufactures and distributes advanced laser-based medical devices, primarily serving the ophthalmology and aesthetic medicine sectors. It supplies products to healthcare providers, clinics and medical facilities across North America, Europe, Asia Pacific and other regions, delivering minimally invasive solutions for eye disease treatment and cosmetic procedures.

Ispire Technology Inc. is a global tech firm specializing in R&D, manufacturing and sales of advanced vaporization hardware and supporting consumables. It serves nicotine and legal cannabis consumer markets, operates two core segments of hardware and branded cannabis products, covers North America, Europe and Asia-Pacific, delivering compliant innovative vapor solutions for B2B partners and end users.

IRIX vs ISPR — Head-to-Head

Bigger by revenue
ISPR
ISPR
1.4× larger
ISPR
$20.3M
$14.7M
IRIX
Growing faster (revenue YoY)
ISPR
ISPR
+18.2% gap
ISPR
-51.5%
-69.7%
IRIX
Faster 2-yr revenue CAGR
IRIX
IRIX
Annualised
IRIX
11.9%
-17.8%
ISPR

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
IRIX
IRIX
ISPR
ISPR
Revenue
$14.7M
$20.3M
Net Profit
$-6.6M
Gross Margin
37.2%
17.1%
Operating Margin
-33.9%
Net Margin
-32.5%
Revenue YoY
-69.7%
-51.5%
Net Profit YoY
17.4%
EPS (diluted)
$-0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IRIX
IRIX
ISPR
ISPR
Q4 25
$14.7M
$20.3M
Q3 25
$12.5M
$30.4M
Q2 25
$13.6M
$20.1M
Q1 25
$11.9M
$26.2M
Q4 24
$12.7M
$41.8M
Q3 24
$11.6M
$39.3M
Q2 24
$12.6M
$37.3M
Q1 24
$11.8M
$30.0M
Net Profit
IRIX
IRIX
ISPR
ISPR
Q4 25
$-6.6M
Q3 25
$-1.6M
$-3.3M
Q2 25
$-994.0K
$-14.8M
Q1 25
$-1.7M
$-10.9M
Q4 24
$-834.0K
$-8.0M
Q3 24
$-1.9M
$-5.6M
Q2 24
$-2.7M
$-3.5M
Q1 24
$-3.5M
$-5.9M
Gross Margin
IRIX
IRIX
ISPR
ISPR
Q4 25
37.2%
17.1%
Q3 25
32.1%
17.0%
Q2 25
34.5%
12.3%
Q1 25
42.5%
18.2%
Q4 24
44.0%
18.5%
Q3 24
37.3%
19.5%
Q2 24
40.7%
28.3%
Q1 24
37.9%
20.4%
Operating Margin
IRIX
IRIX
ISPR
ISPR
Q4 25
-33.9%
Q3 25
-11.3%
-8.9%
Q2 25
-6.9%
-72.7%
Q1 25
-1.7%
-40.4%
Q4 24
-3.9%
-17.6%
Q3 24
-16.1%
-13.4%
Q2 24
-20.9%
-9.2%
Q1 24
-28.0%
-18.8%
Net Margin
IRIX
IRIX
ISPR
ISPR
Q4 25
-32.5%
Q3 25
-12.6%
-10.7%
Q2 25
-7.3%
-73.4%
Q1 25
-14.2%
-41.5%
Q4 24
-6.6%
-19.1%
Q3 24
-16.7%
-14.2%
Q2 24
-21.2%
-9.4%
Q1 24
-29.5%
-19.7%
EPS (diluted)
IRIX
IRIX
ISPR
ISPR
Q4 25
$-0.12
Q3 25
$-0.09
$-0.06
Q2 25
$-0.06
$-0.26
Q1 25
$-0.10
$-0.19
Q4 24
$-0.05
$-0.14
Q3 24
$-0.12
$-0.10
Q2 24
$-0.16
$-0.07
Q1 24
$-0.21
$-0.11

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IRIX
IRIX
ISPR
ISPR
Cash + ST InvestmentsLiquidity on hand
$6.0M
$17.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$-7.7M
Total Assets
$29.2M
$84.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IRIX
IRIX
ISPR
ISPR
Q4 25
$6.0M
$17.6M
Q3 25
$5.6M
$22.7M
Q2 25
$6.8M
$24.4M
Q1 25
$7.2M
$23.5M
Q4 24
$2.4M
$34.4M
Q3 24
$3.9M
$37.7M
Q2 24
$4.1M
$35.1M
Q1 24
$5.4M
$39.5M
Total Debt
IRIX
IRIX
ISPR
ISPR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$1.0M
Q3 24
$1.4M
Q2 24
Q1 24
Stockholders' Equity
IRIX
IRIX
ISPR
ISPR
Q4 25
$-7.7M
Q3 25
$4.7M
$-1.8M
Q2 25
$6.1M
$604.7K
Q1 25
$852.0K
$14.8M
Q4 24
$2.1M
$24.2M
Q3 24
$2.6M
$30.7M
Q2 24
$4.2M
$34.5M
Q1 24
$6.5M
$35.9M
Total Assets
IRIX
IRIX
ISPR
ISPR
Q4 25
$29.2M
$84.4M
Q3 25
$28.4M
$96.4M
Q2 25
$31.6M
$102.2M
Q1 25
$34.2M
$115.7M
Q4 24
$29.1M
$132.0M
Q3 24
$30.2M
$129.0M
Q2 24
$31.2M
$122.6M
Q1 24
$34.1M
$108.0M
Debt / Equity
IRIX
IRIX
ISPR
ISPR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.48×
Q3 24
0.53×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IRIX
IRIX
ISPR
ISPR
Operating Cash FlowLast quarter
$-4.0M
Free Cash FlowOCF − Capex
$-4.0M
FCF MarginFCF / Revenue
-19.9%
Capex IntensityCapex / Revenue
0.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-14.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IRIX
IRIX
ISPR
ISPR
Q4 25
$-4.0M
Q3 25
$-1.2M
$-1.2M
Q2 25
$-397.0K
$4.7M
Q1 25
$-1.1M
$-12.5M
Q4 24
$-1.2M
$-3.2M
Q3 24
$-3.1M
$3.6M
Q2 24
$-1.3M
$-1.4M
Q1 24
$-1.6M
$3.4M
Free Cash Flow
IRIX
IRIX
ISPR
ISPR
Q4 25
$-4.0M
Q3 25
$-1.2M
$-1.2M
Q2 25
$-410.0K
$3.7M
Q1 25
$-1.2M
$-12.7M
Q4 24
$-1.2M
$-3.2M
Q3 24
$-3.1M
$3.3M
Q2 24
$-2.2M
Q1 24
$-1.7M
$3.3M
FCF Margin
IRIX
IRIX
ISPR
ISPR
Q4 25
-19.9%
Q3 25
-9.4%
-3.9%
Q2 25
-3.0%
18.6%
Q1 25
-9.8%
-48.4%
Q4 24
-9.8%
-7.7%
Q3 24
-26.5%
8.5%
Q2 24
-5.9%
Q1 24
-14.0%
10.9%
Capex Intensity
IRIX
IRIX
ISPR
ISPR
Q4 25
0.3%
Q3 25
0.1%
0.0%
Q2 25
0.1%
4.8%
Q1 25
0.1%
0.7%
Q4 24
0.1%
0.1%
Q3 24
0.0%
0.7%
Q2 24
0.0%
2.0%
Q1 24
0.0%
0.3%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons